Pyoderma gangrenosum associated with ulcerative colitis treated with infliximab

Resumen

Abstract

Pyoderma gangrenosum is an uncommon destructive and infl ammatory skin disease of the neutrophilic dermatosis group. Of unknown etiology, it is
possibly an immunological disorder. Infl iximab is an anti-tumor necrosis factor alpha monoclonal antibody. We report 3 patients with ulcerative colitis
and recalcitrant pyoderma gangrenosum not responsive to conventional therapies and treated with infl iximab with favorable results. Seemingly,
infl iximab is an eff ective and well tolerated drug for the treatment of pyoderma gangrenosum associated with ulcerative colitis

(Dermatol Argent 2009; 15(3):191-195).

Key words: anti-tumor necrosis factor alpha, infl ammatory bowel disease, infl iximab, pyoderma gangrenosum, ulcerative colitis.